Cygnus Technologies

What Cygnus Technologies does

Cygnus Technologies, LLC is a biotechnology company specializing in the detection and quantification of process-related impurities in biopharmaceutical manufacturing. Founded in 1998 and headquartered in Southport, North Carolina, the company operates as a wholly-owned subsidiary of Maravai LifeSciences (NASDAQ: MRVI) and has built a 25-plus-year track record supplying Host Cell Protein (HCP) ELISA kits, bioprocess impurity assays (Protein A, Protein L, residual DNA), and the MockV viral clearance prediction platform to global biopharma manufacturers. The product portfolio spans 21+ cell-line-specific HCP ELISA kits, the AccuRes Host Cell DNA quantification kits, and the MockV family of BSL-1-compatible non-infectious viral surrogates (RVLP and MVM) used in lieu of live-virus spiking studies.

The company's underlying technology rests on proprietary immunoassay and mass spectrometry methods, including Antibody Affinity Extraction (AAE), AAE-MS, the HCP inSPECt DIA-based quantification platform, and the CHO 6xLipase PRM-MS targeted proteomic assay. These orthogonal methods address the limitations of legacy 2D Western blot coverage analysis and provide ppm-level sensitivity for high-risk impurities such as polysorbate-degrading lipases. Cygnus also offers custom antibody and assay development, assay qualification, and viral clearance services delivered by technical experts, complementing its catalog products.

Cygnus generates revenue through two primary streams: one-time sales of catalog kits and reagents (priced from roughly $24 to $4,863 per kit, with consumable repeat orders), and project-based custom development services for HCP antibody coverage, assay qualification, and viral clearance studies. The go-to-market combines a direct e-commerce storefront, enterprise field sales with customer account managers, an international distributor network for global reach, and active participation in industry conferences such as Bioprocessing Summit 2026 and Bioproduction Congress 2026. Customers include biopharmaceutical companies developing monoclonal antibodies, biosimilars, vaccines, and advanced therapy medicinal products, with HCP kits qualified into regulatory submissions for multiple marketed biologics.

Name

Cygnus Technologies

Legal name

Cygnus Technologies, LLC

Website

https://cygnustechnologies.com

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

1–10 employees

Short description

Cygnus Technologies, a Maravai LifeSciences subsidiary, supplies Host Cell Protein ELISA kits, MockV viral clearance prediction kits, AccuRes DNA kits, and orthogonal mass spectrometry services to global biopharmaceutical manufacturers for impurity detection and regulatory compliance.

Ownership category

akta.pro rank

Product category

Bioprocess Impurity Analytics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

akta.pro secondary industry

Cell-Based & Potency Assays (Bioassays) (HLAGADAH)

Keywords

• Bioprocess impurity testing
• Host cell protein analytics
• Viral clearance kits
• Biopharmaceutical reagents
• Custom assay development

Headquarters

HQ city

Southport

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Diagnostic Kits and Reagents: Sale of HCP ELISA kits, viral clearance MockV kits, host cell DNA kits, antibodies, and immunoassay reagents. One-time purchase model with repeat customer orders for consumables and replenishment.
2. Custom Development Services: Contract research services including HCP antibody coverage analysis, assay qualification and sample testing, custom antibody and assay development, viral clearance services, and HCP identification and quantification. Project-based professional services.

Pricing tiers

Go-to-market motion4 records

Distribution channels3 records

Marketing channels5 records

Core offering

Cygnus Technologies develops and sells proprietary immunoassay kits, mass spectrometry-based services, and contract analytical services for detecting and quantifying bioprocess impurities (host cell proteins, residual DNA, Protein A/L, viral contaminants) during biopharmaceutical manufacturing. Core offerings include HCP ELISA kits for 21+ cell lines, MockV BSL-1 viral clearance prediction kits, AccuRes Host Cell DNA kits, and orthogonal HCP characterization services using Antibody Affinity Extraction (AAE) and mass spectrometry.

Product overview

Cygnus Technologies offers a comprehensive portfolio of bioprocess impurity detection and analytics products and services for the biopharmaceutical industry. The core offering includes Host Cell Protein (HCP) ELISA kits for 21 cell lines, Bioprocess Impurity ELISA kits (Protein A, Protein L, and other process-related impurities), and AccuRes™ Host Cell DNA quantification kits. The company's innovative MockV® viral clearance prediction platform includes RVLP Kits (with 2G version) and MVM Kits for BSL-1 compatible viral clearance testing, along with associated reagents and services. Supporting services encompass Antibody Affinity Extraction (AAE™), mass spectrometry-based HCP quantification (HCP inSPECt™ and CHO 6xLipase™ MS assays), custom antibody and assay development, and viral clearance services. The portfolio is designed to support biopharmaceutical manufacturers from preclinical development through commercial manufacturing lot release, with all products accepted by global regulatory agencies.

Differentiator

Problem solved

Functional benefit

Brands

• AccuRes: AccuRes Host Cell DNA Kits for extraction and quantification of host cell DNA with real-time PCR instruments.
• MockV
• HCP inSPECt
• CHO 6xLipase MS Assay
• AAE-MS

Products and services

• Host Cell Protein ELISA Kits

Quantifiable outcome

• RVLP detection sensitivity of 1 x 10^3 RVLP/mL, enabling LRV of ~5.0 to be determined
• +4 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature9 records

Partnerships

Two partnerships are on record, tiered notable.

• Dyadic International Inc.notableStrategic or Co-development Partner · 1 February 2024In February 2024, Dyadic International Inc. partnered with Cygnus Technologies LLC to develop a C1 HCP ELISA test for quality assurance in biomanufacturing. This partnership leverages Dyadic's C1 expression platform capabilities with Cygnus' HCP assay expertise.
• UCBnotableStrategic or Co-development PartnerValidation studies for the MockV RVLP inactivation kit were conducted in collaboration with UCB, confirming the assay's efficacy across different detergent types and in-process material samples.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Bio-Techne: Bio-Techne (R&D Systems, ProteinSimple, Tocris brands) sells HCP ELISA kits, antibodies, and protein analysis reagents directly competing with Cygnus's core bioprocess impurity detection portfolio. Both serve biopharmaceutical manufacturers with immunoassay-based process analytics.
• Charles River Laboratories: Charles River provides viral clearance CRO services and bioprocess testing that overlaps with Cygnus's MockV viral clearance services and HCP analytical offerings. Both compete for biologics manufacturing QC budgets, with Charles River operating a broader CRO model.
• Roche Custom Biotech: Roche's Custom Biotech division offers CHO HCP ELISA kits and bioprocess analytics reagents directly competitive with Cygnus's HCP ELISA portfolio. Roche's larger commercial reach and bundled offerings make it a primary incumbent competitor in HCP analytics.
• Eurofins Scientific: Eurofins provides biopharmaceutical product testing services including HCP ELISA, viral clearance, and mass spectrometry-based characterization. Eurofins's global laboratory network competes with Cygnus's contract services business for outsourced bioprocess analytics.
• Repligen: Repligen supplies bioprocess analytics, chromatography, and filtration products to biologics manufacturers. The company's analytics franchise competes with Cygnus's HCP detection and process impurity testing offerings for biopharmaceutical process development budgets.

Broad incumbents

• Cytiva: Cytiva (Danaher) provides bioprocess reagents, analytics, and purification tools to biologics manufacturers. While broader in scope than Cygnus, Cytiva competes in HCP detection and bioprocess impurity analytics through its bioprocess characterization portfolio.
• Sartorius: Sartorius is a leading bioprocess equipment and consumables supplier serving monoclonal antibody and vaccine manufacturers. The company offers analytical solutions that overlap with Cygnus's bioprocess impurity detection and is increasingly bundling analytics with upstream/downstream bioprocess platforms.
• Thermo Fisher Scientific: Thermo Fisher offers mass spectrometry instruments, bioprocess analytics, and CDMO services that overlap with Cygnus's MS-based HCP services and viral clearance testing. As the largest life sciences tools provider, it represents both a competitor and a potential channel for Cygnus's analytical methods.
• WuXi AppTec: WuXi AppTec provides comprehensive biopharmaceutical testing and CRO/CDMO services including viral clearance and bioprocess analytics. While broader in scope, WuXi's testing services compete with Cygnus's contract analytical services for global biologics manufacturer customers.
• Aldevron: Aldevron (Danaher) provides bioprocess services including plasmid DNA, mRNA, and protein production for vaccine and gene therapy developers. As a Danaher bioprocess platform, Aldevron increasingly overlaps with Cygnus's HCP analytics for novel modality manufacturing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCHDRNr_lrxaMbR24YnvCvyg
• LinkedInlinkedin.com/company/cygnus-technologies-inc.
• Xx.com/cygnustechno

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cygnus Technologies